IMMY

Executive Summary

IMMY is a privately-held U.S. diagnostics company founded in 1979, specializing in fungal disease diagnostics. With a portfolio spanning lateral flow assays, enzyme immunoassays, PCR tests, and traditional methods, the company has established a strong presence in global markets. Its mission to provide fast, reliable, and accessible fungal diagnostics addresses a significant unmet need, as fungal infections pose a growing burden worldwide. While IMMY lacks recent funding or valuation data, its long operating history and diverse product lineup suggest resilience and steady market penetration. The company's focus on a niche but critical area positions it for sustained demand, though limited public information constrains assessment of near-term growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance of a new point-of-care fungal diagnostic test70% success
• Q4 2026Strategic partnership with a global diagnostics distributor to expand into Asia-Pacific60% success
• Q2 2026Positive clinical study results for a novel Candida auris detection assay75% success